Phase III Clinical & Commercial cGMP Manufacturing Agreement Signed by Celtic Pharma and QSV Biologics, Ltd., for TransMID

12-Jan-2007

QSV Biologics, Ltd (QSV) and Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) announced the signing of a cGMP manufacturing agreement for TransMID(TM). QSV will be responsible for cGMP manufacture of further phase III clinical trial material and longer term commercial manufacture in their licensed cGMP manufacturing facility. TransMID(TM) is being developed for the specific treatment of progressive and recurrent non-resectable glioblastoma multiforme, a particularly dangerous type of brain tumor where the average life expectancy is less than six months upon diagnosis.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances